Registration is open!
The Diabetes epidemic is pervasive. In 2019, 59 million adults in Europe were living with diabetes and this figure is forecasted to rise to 66 million by 2030. This has and will have wide-ranging ramifications for society at large. Diabetes-related costs account for around 9% of total health expenditure (approx. €100 billion per annum), 75% of which is due to preventable complications. Diabetes reduces the life expectancy of people aged 40-60 by 4-10 years and is causally linked to other non-communicable diseases such as cancer and cardiovascular disease. Additionally, in 2015 people living with diabetes accounted for the third-largest number of potentially avoidable hospitable bed days spent in Europe, among all the major chronic diseases.
With both the Council and the Parliament securing their negotiating mandates, the first trilogue on the Health Technology Assessment (HTA) Regulation was scheduled to take place at the end of April.
With COVID-19 continuing to disrupt our lives and limiting people’s movements, carrying out clinical trials has been particularly challenging over the past year. This comes on top of the hurdles typically faced in traditional trials, especially regarding participant recruitment and retention.